Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19
Prasan Kumar Panda,1 Budha O Singh,1 Bikram Moirangthem,1 Yogesh Arvind Bahurupi,2 Sarama Saha,3 Girraj Saini,4 Minakshi Dhar,1 Mukesh Bairwa,1 Venkatesh Srinivasa Pai,1 Ankit Agarwal,5 Girish Sindhwani,6 Shailendra Handu,7 Ravi Kant8 1Department of Medicine (Infectious Disease Division), All India...
Guardado en:
Autores principales: | Panda PK, Singh BO, Moirangthem B, Bahurupi YA, Saha S, Saini G, Dhar M, Bairwa M, Pai VS, Agarwal A, Sindhwani G, Handu S, Kant R |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ef18526da9d24a08a14f2c889febc7a4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial
por: A. Abayomi, et al.
Publicado: (2021) -
Interacciones farmacológicas en niños con infección por VIH en tratamiento con antirretrovirales
por: Castro-Moraga,María Eugenia, et al.
Publicado: (2021) -
Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review
por: Alina Kröker, et al.
Publicado: (2021) -
An early assessment of the efficacy of medicines in the treatment of patients with COVID-19
por: A. S. Kolbin
Publicado: (2020) -
Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy
por: Linhu Ye, et al.
Publicado: (2021)